Vishnupriya
New Delhi: Fortis Hospital’s diagnostics arm, Agilus Diagnostics, has launched a genome test designed to detect cancer with a three-day turnaround time (TAT) for test results in myeloid malignancies. The test also provides comprehensive genomic profiling for cancers such as lung, colon, breast, and melanoma.
The Myeloid genomics test analyzes 79 genes, including those associated with inherited risks, to identify key genetic changes such as mutations and fusions. This enables personalized treatment recommendations for conditions like Acute Myeloid Leukemia (AML) and Myeloproliferative Neoplasms (MPN), the company stated.
The test identifies mutations, amplifications, and fusion genes, offering actionable insights for targeted treatments. With optimized panels for tissue and blood samples, it ensures accurate results for both liquid biopsy samples and tissue block samples, the company added.
“With our advanced genomic testing capabilities, we aim to provide clinicians with the tools they need to make timely, informed decisions. This not only improves outcomes but also sets a new benchmark for the healthcare industry in India,” said Dr Anand K, Managing Director & CEO of Agilus Diagnostics.
The Indian genome testing market is currently valued at approximately $150 million and is projected to grow at a CAGR of over 15 per cent in the next five years. Genomic testing is transforming cancer diagnostics by offering actionable insights into an individual’s unique genetic profile. It enables clinicians to identify specific mutations, tailor treatment plans, and select therapies with the highest efficacy.
